Victory Capital Management
CRVS icon

Victory Capital Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Victory Capital Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.88M Buy
+128,352
New +$2.05M ﹤0.01% 1614
2020
Q2 		– Sell
-8,034
Closed -$16K – 2685
2020
Q1 		$16K Buy
+8,034
New +$32.6K ﹤0.01% 3159
2019
Q4 		– Sell
-3,538
Closed -$11K – 2780
2019
Q3 		$11K Buy
+3,538
New +$14.8K ﹤0.01% 3223

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Victory Capital Management's CRVS Position: Q1 2026 in Review

Victory Capital Management opened a new position in Corvus Pharmaceuticals (CRVS) in Q1 2026: 128,352 shares worth $1.88M. The stake represents ﹤0.01% of the portfolio and ranks #1614 among its holdings. This is a return to the name: Victory Capital Management previously reported a position in CRVS as recently as Q1 2020.

Victory Capital Management first reported a position in CRVS in Q3 2019 and has held it in 3 quarters since. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Victory Capital Management held 128,352 shares of Corvus Pharmaceuticals worth $1.88M as of Q1 2026.
  • Corvus Pharmaceuticals was a new Victory Capital Management position in Q1 2026.
  • Corvus Pharmaceuticals made up ﹤0.01% of Victory Capital Management's portfolio in Q1 2026, its #1614 holding.
  • Victory Capital Management first reported a position in Corvus Pharmaceuticals in Q3 2019 and has held it in 3 quarters since.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Victory Capital Management's 13F filing for Q1 2026, filed 15 May 2026.